Exclusive Summary

• Highly Innovative First-in-class Mechanism: As a pioneering cell-free, non-exosomal stem cell-derived protein complex, it uses a multi-target network reconstruction approach to intervene in the complex pathology of Alzheimer's Disease (AD).
• Breaking the Efficacy Bottleneck: It has the potential to break the limitations of existing single-target drugs that merely 'delay decline' by rescuing the mitochondrial-lysosomal axis and reducing neuroinflammation, driving true functional recovery.
• Overcoming CNS Delivery & CMC Barriers: It demonstrates exceptional BBB penetration (1.17% via IV, 10.6% via IT) and boasts a fully standardized, scalable manufacturing process with significantly lower costs than traditional cell therapies.
• Massive and Clear Market Potential: With over 55 million AD patients globally and an economic burden in the hundreds of billions, its disruptive disease-modifying potential addresses a massive unmet clinical need.
• Exceptional License-out Value for Global Pharmas: The asset is already de-risked by ongoing IIT preliminary data and the core UBD001 platform's human validation across multiple CNS indications, offering MNCs a low-risk, high-potential pipeline expansion.

Asset Materials

Contact Us for Full Materials